Prescription medicine
Lebrikizumab Brand names: Ebglyss
Lebrikizumab (Ebglyss) is a prescription medicine. No generic is listed; pharmacies paid $1,783.52 per mL (Ebglyss 250 mg/2 mL pen) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the lebrikizumab FDA label on DailyMed (effective June 9, 2026); every lebrikizumab label on DailyMed.
Highlights of the record
FDA label of June 9, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageEBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Forms and strengths
- 250 mg/2ml
Injection (solution).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $1,783.52 per mL Ebglyss 250 mg/2 mL pen
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is lebrikizumab used for?
From the label: indications and usageEBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. EBGLYSS ® is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. […]
Conditions named in the indications of lebrikizumab's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Interleukin-13 Antagonist.
Source: FDA drug label (EBGLYSS), Eli Lilly and Company, effective June 9, 2026 (SPL set 7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5f), via openFDA; the full label on DailyMed
Is there a generic for lebrikizumab (Ebglyss)?
No generic lebrikizumab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for lebrikizumab (Ebglyss)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $1,783.52 per mL (Ebglyss 250 mg/2 mL pen). The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Ebglyss 250 mg/2 mL pen (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ebglyss 250 mg/2 mL pen | Brand | $1,783.52 per mL | $3,567.05 per pen | n/a |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What else is labeled for the same conditions as lebrikizumab?
3 other medicines are given the same way (subcutaneous) and in the same FDA class as lebrikizumab or labeled mainly for the same use (eczema (atopic dermatitis)), the same class first. Eczema (atopic dermatitis) lists all 26 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Tralokinumab | Eczema (atopic dermatitis) | none listed | n/a | No current entry |
| Dupilumab | Eczema (atopic dermatitis) | none listed | $1,773.74 per mL 200 mg/1.14 mL syring | No current entry |
| Nemolizumab | Eczema (atopic dermatitis) | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as lebrikizumab
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to lebrikizumab
- 3 medicines for the same use
- Other interleukin-13 antagonists
- the pharmacologic class, with prices and generics
- Check an interaction
- what two or more labels say about each other